Accumulating evidence supports a role for STAT proteins also in resistance to EGFR inhibitors in several preclinical models, including glioma, head and neck squamous cell carcinoma (HNSCC), and non-small cell lung cancer (NSCLC) [70, 71]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.